However, the sole blockade of TIGIT showed limited antitumor efficacy, while the blockade of TIGIT in combination with anti-PD-1/PD-L1 therapy showed enhanced antitumor effect in mice even in anti-PD-1-resistant tumor models [205,207]. This evidence concerns the gene TIGIT and neoplasm.